Fig 1: Inhibiting IL-1 signalling with IL1β inhibitor MLX01, Caspase-1 inhibitor VX765 and IL1R antagonist Anakinra reduced metastatic outgrowth from E0771 cells disseminated in the bone. (A) Outline of experimental protocol for administration of PBS (control), MLX01, VX765 and Anakinra in mice following intra-cardiac injection of E0771. (B) Representative whole body IVIS images of mice at Day 8 and Day 15 post injection of E0771 cells. (C) Numbers of overt metastases per mouse 8-, 15- and 16-days post injection of E0771 cells following daily administration of PBS (control), MLX01, VX765 or Anakinra. (D) Total luciferase expression (photons per second (P/S)) of whole mice 8 and 15 days after E0771 cell injection. (E) Numbers of mice that developed bone metastases 8, 15 and 16 days after E0771 cells had been disseminated in the bone following daily administration of PBS (control) MLX01, VX765 or Anakinra. (F) Size of tumours that grew in the bone as assessed by photons per second (P/S) in luciferase expressing E0771 tumour cells. (G) Shows effects of PBS (control), MLX01, VX765 or Anakinra on metastatic outgrowth of tumours following dissemination into the lungs, kidneys and livers. (H) Protocol outline for administration of Pacritinib in mice after intra-cardiac injection of E0771. (I) Representative images of whole body IVIS imaging 17 days post E0771 injection. (J) Numbers of overt metastases per mouse 17 days post injection of E0771 cells and following daily administration of PBS (control), or Pacritinib. (K) Total luciferase signal from E0771 tumour cells (photons per second (P/S)) in whole mice 17 days following injection of E0771 cells and administration of PBS (control) or Pacritinib. (L) Numbers of mice that developed bone metastases 17 days after E0771 cells had been disseminated in the bone following daily administration of PBS (control) or Pacritinib and size of tumours that grew in the bone as assessed by IVIS imaging in (M). (N) Shows effects of PBS (control), or Pacritinib on metastatic outgrowth of tumours following dissemination into the lungs, kidneys and livers. *** p < 0.001, **** p < 0.0001.
Fig 2: The effect of inhibiting signalling of the IL-1 pathway on growth of E0771 cells in mammary glands and spontaneous metastasis to lung and bone (A) Protocol outline for orthotopic injection of E0771 cells into mammary glands and administration of PBS (control), MLX01, VX765 or Anakinra in mice. (B) Primary tumour volume following daily administration of PBS (control), MLX01, VX765 or Anakinra. (C) Survival curve (D) IVIS images of dissected femur/tibia ex vivo following exposure to D-luciferin for 5 min. (E) Percentage of mice that developed spontaneous bone metastasis and size of tumours in femurs/tibiae as assessed ex vivo by IVIS. (F) IVIS images of dissected lungs, ex vivo (G) Percentage of mice that developed spontaneous lung metastasis and size of tumours in lungs as assessed by IVIS, ex vivo. The graphs represent mean ± SD, * p < 0.05, ** p < 0.01, **** p < 0.0001.
Fig 3: Tfcp2l1 restrains the AT2 cell response to IL-1 signaling(A) Experimental schematic showing the days for cytokine treatments and duration of organoid culture.(B) Organoids treated with PBS or IL-1b as noted. Lineage-marked cells are from native EYFP fluorescence, and IHC on sections for SFTPC and AGER expression reveals AT2 and AT1 cells, respectively (lineage panel bar graph, 1,000 μm; IHC bar graph, 50 μm).(C) Quantification of organoid size after 21 days in culture, comparing PBS and IL-1β in control and Tfcp2l1AT2-KO.(D) Summary diagram showing that Tfcp2l1 represses AT2 cell proliferation and inflammatory signaling.(E) Left: Tfcp2l1 is enriched in AT2 cells. The lack of Tfcp2l1 transient increases cell proliferation during lung regeneration. Right: Tfcp2l1 maintains AT2 cell identity and reduces AT2-AT1 cell differentiation.All data quantification data are represented as mean ± SEM. two-way ANOVA, Tukey test, and not significant; p ≤ 0.05, n = 3 mice per group.
Supplier Page from BioLegend for Recombinant Mouse IL-1β (carrier-free)